Enhanced Fluorescent Detection of Pathogens

Information

  • Research Project
  • 6882203
  • ApplicationId
    6882203
  • Core Project Number
    R43AI058445
  • Full Project Number
    1R43AI058445-01A1
  • Serial Number
    58445
  • FOA Number
    PAS-02-149
  • Sub Project Id
  • Project Start Date
    3/15/2005 - 20 years ago
  • Project End Date
    2/28/2007 - 18 years ago
  • Program Officer Name
    BREEN, JOSEPH J.
  • Budget Start Date
    3/15/2005 - 20 years ago
  • Budget End Date
    2/28/2006 - 19 years ago
  • Fiscal Year
    2005
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    3/3/2005 - 20 years ago
Organizations

Enhanced Fluorescent Detection of Pathogens

DESCRIPTION (provided by applicant): The goal of this application is the development of an ultrahigh sensitivity microarray platform for the simultaneous detection of many NIAID category A-C pathogens or pathogen byproducts. The application centers on the integration of two technologies; the world's brightest fluorophores and metal enhanced fluorescent characteristics of silver nanocomposites. Successful completion of the project would provide an extremely reliable platform that delivers high sensitivity in a fast, direct and easy to use manner for the detection of many pathogens on a protein microchip. The Phase I project will first research the feasibility of reliably manufacturing silver/silica nanocomposites. Secondly, the chemical attachment of these nanocomposites to algal- derived fluorescent photosystems and the self-assemblage of nanocomposite films onto a glass slide to develop the detection platform. Next, benchmarking and optimization of the detection platform against current commercial microarray based cytokine assays. Finally, detecting six different NIAID Category A-C priority pathogens simultaneously at a sensitivity level over an order of magnitude greater than currently employed technology. The development of this platform would be a dramatic improvement in pathogen detection technology. These improvements would include an increase in the detection limits that would allow for earlier detection of pathogenic agents. Earlier intervention/treatment of the infectious agent will result in higher survival rates and positive outcomes.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    454196
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:454196\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MICROCOSM, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    COLUMBIA
  • Organization State
    MD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    21045
  • Organization District
    UNITED STATES